Clinical trials: Pregnancy, Multiple
Polycystic Kidney Diseases
Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease
Chronic Kidney Disease (CKD) is associated with bone changes and very high fracture rates. A component of bone is marrow. Bone marrow fat is increased in patients with CKD compared to those in the normal population of the same…
- Trial name
- NCT02739750
- Testing
- No intervention
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Glomerulonephritis , IGA
The Clinical Trial of ADR-001 for IgA Nephropathy
The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.
- Trial name
- NCT04342325
- Testing
- infusion of ADR-001 (Mesenchymal stem cell)
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Nagoya University
End Stage Renal Failure
Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients
The purpose of this study is to establish the therapeutic equivalence of Gengraf® with the standard treatment Neoral® for a treatment period of 6 months in stable renal allograft transplant recipients with respect to drug levels…
- Trial name
- NCT01990118
- Testing
- Neoral, Gengraf® capsule containing 25mg or 100mg cyclosporine
- Where
- Malaysia
- Volunteers
- 106 people
- Sponsor
- Penang Hospital, Malaysia
Pruritus, Cholestasis
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.
- Conditions
- Pruritus, Cholestasis, Kidney Failure
- Trial name
- NCT04510090
- Testing
- EP547
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Escient Pharmaceuticals, Inc
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Papillary Renal Cell Carcinoma
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally…
- Trial name
- PRCC (NCT07024680)
- Testing
- Observational, None intervention
- Where
- China
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Endometriosis
Visanne Study to Assess Safety in Adolescents
A clinical trial which was designed to demonstrate the safety and efficacy of Visanne (approved in endometriosis for adults) in the adolescent population.
- Trial name
- VISADO (NCT01283724)
- Testing
- Dienogest (Visanne, BAY86-5258)
- Where
- 36 sites in Austria, Czechia and 4 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Bacterial Vaginosis
Lcr35® for Bacterial Vaginosis Prevention
This is a national, multi-centre, randomized, double-blind placebo-controlled, phase III superiority trial. The main objective of the trial is to assess the efficacy of Lcr35® by comparing the mean time before the onset of the…
- Trial name
- NCT01160796
- Testing
- Lcr35®
- Where
- France
- Volunteers
- 352 people
- Sponsor
- Laboratoires Lyocentre
Renal Failure , Chronic, Graft Failure
Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression…
- Conditions
- Renal Failure , Chronic, Graft Failure, Graft Rejection, Allograft
- Trial name
- NCT06676696
- Testing
- Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months
- Where
- Spain
- Volunteers
- 202 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Autosomal Dominant Polycystic Kidney Disease
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney…
- Trial name
- NCT03487913
- Testing
- Lixivaptan
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Palladio Biosciences
Kidney Diseases, Kidney Injury
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound.
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05777174
- Testing
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 5 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Polycystic Kidney, Autosomal Dominant
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria.
- Trial name
- STOP-PKD (NCT07280585)
- Testing
- Dapagliflozin 10 mg
- Where
- 30 sites in Austria, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- University of Cologne
Bacterial Infections, Urinary Tract Infections
Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts: Part 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of…
- Conditions
- Bacterial Infections, Urinary Tract Infections, Intra-Abdominal Infections, Respiratory Tract Infections
- Trial name
- NCT07207291
- Testing
- JKN2501
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Tumor
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
- Trial name
- CheckMate 76U (NCT04311710)
- Testing
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Polycystic Kidney Diseases
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
- Trial name
- NCT03423810
- Testing
- Hydralazine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Kansas Medical Center
Endometriosis, Moderate to Severe Endometriosis-associated Pain
Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis
The objective of this study is to demonstrate the efficacy and safety of BG2109 administered orally once daily at a dose of 100 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1…
- Trial name
- NCT05894135
- Testing
- BG2109 100mg, BG2109 200mg, ABT(E2 1 mg / NETA 0.5 mg)
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
Pruritus, Kidney Failure, Chronic
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Uremic pruritus is a clinically significant symptom which imposes heavy impact on the quality of life of patients with chronic kidney disease undergoing hemodialysis.
- Trial name
- NCT02432508
- Testing
- Laser acupuncture (Olympic)
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.